Key statistics
On Friday, Roivant Sciences Ltd (87S:STU) closed at 24.30, -1.54% below its 52-week high of 24.68, set on Feb 25, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 23.71 |
|---|---|
| High | 24.36 |
| Low | 23.66 |
| Bid | 24.41 |
| Offer | 24.60 |
| Previous close | 24.04 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 715.70m |
| Free float | 536.47m |
| P/E (TTM) | -- |
| Market cap | 20.71bn USD |
| EPS (TTM) | -1.17 USD |
Data delayed at least 15 minutes, as of Feb 27 2026.
More ▼
Announcements
- Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
- Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
- Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
- Roivant Highlights Continued Pipeline Progress and Outlook for Company’s Next Phase of Growth at 2025 Investor Day
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
- Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
- Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
- Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
- Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
- Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
More ▼
